Clinical reference Biomarker Directory
Back to directory

Insulin-like Growth Factor-Binding Protein-1

Emerging

IGFBP-1 is the basis of a rapid bedside test (Actim PROM) for diagnosing preterm rupture of membranes in pregnancy.

Also known as IGFBP-1 IGF-binding protein 1
In plain language

This protein has two very different uses: as a research marker of insulin sensitivity in conditions like PCOS, and as the basis of a quick bedside test that helps confirm whether a pregnant woman's water has broken early, since this protein is normally found almost only in amniotic fluid.

Biomarker & context

IGFBP-1 is a protein that binds and regulates the bioavailability of insulin-like growth factors; its level rises with increasing insulin sensitivity, giving it a role as a research marker in metabolic conditions.

What it indicates

Levels are studied as a research marker in PCOS and insulin resistance (where IGFBP-1 tends to be suppressed), and IGFBP-1 has a distinct, practical obstetric application unrelated to its metabolic role.

Diagnosis & clinical testing

IGFBP-1 is the basis of a commercial rapid bedside test (marketed as Actim PROM) used to help diagnose preterm premature rupture of membranes, since IGFBP-1 is highly concentrated in amniotic fluid but nearly absent from vaginal secretions and cervical mucus otherwise.

Guiding treatment

A positive Actim PROM test in a pregnant patient with suspected membrane rupture supports the diagnosis and informs decisions about preterm labor management, antibiotic prophylaxis, and delivery timing, offering a practical, rapid bedside alternative to more subjective clinical assessment alone.

Clinical significance

A practical clinical application distinct from its research role as a metabolic/insulin sensitivity marker.

References
  1. General obstetric reference literature on the IGFBP-1-based Actim PROM test for diagnosing preterm premature rupture of membranes.